Assessing Your Asthma is Key to Taking Control
WILMINGTON, Del., May 13, 2013
WILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million
Americans suffer from asthma, which accounts for more than 3300 deaths each
year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma &
Allergy Awareness Month this May by taking proactive steps to gain control of
their asthma and learn more about how it may be impacting their lives.
To view the multimedia assets associated with this release, please click:
People living with asthma have inflammation, also known as swelling, in their
airways. When left uncontrolled, the inflammation makes their airways more
sensitive to common asthma triggers like pollen, dust, and smoke. Exposure to
these asthma triggers can cause the muscles around the airways to tighten,
leading to asthma symptoms like shortness of breath, wheezing, tightness of
the chest, and coughing. Medicines that help to control asthma can help
control the inflammation and help reduce sensitivity to asthma triggers.
"It is important for patients with asthma to gain control of their symptoms on
an ongoing basis, allowing them to live their lives with fewer interruptions –
asthma doesn't have to limit their daily activities," said Frank Trudo, MD,
Medical Affairs, AstraZeneca. "National Asthma and Allergy Awareness Month is
an opportune time for patients with asthma to work with their health care
providers, reexamine asthma triggers and symptoms, to determine if their
asthma is under control and their lungs are functioning optimally."
A doctor may recommend controlling asthma symptoms with SYMBICORT^®
(budesonide/formoterol fumarate dihydrate) inhalation aerosol, a combination
of inhaled corticosteroid (ICS) and long-acting beta-adrenergic agonist
(LABA). SYMBICORT is a medicine, which contains two medicines to reduce the
inflammation in the lungs and keep airways open. SYMBICORT helps to control
asthma in appropriate patients who are 12 years or older and who are
uncontrolled on an ICS or whose disease severity clearly warrants an ICS/LABA
therapy. When used as prescribed, SYMBICORT has been shown to help
significantly improve lung function, starting within 15 minutes.* SYMBICORT
will not replace a rescue inhaler for sudden symptoms.
AstraZeneca is committed to helping people living with asthma. By visiting
www.mysymbicort.com/asthma, patients can access a number of useful multimedia
disease management resources, including anAsthma Assessment quiz, a tool to
help patients and their doctors determine their level of asthma control and
the impact asthma has on their lives and a free prescription offer to save on
the cost of SYMBICORT.
Please see full Prescribing Information, including Boxed WARNING.
*Your results may vary.
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
oWARNING: Long-acting beta-adrenergic agonists (LABA), such as
formoterol, one of the active ingredients in SYMBICORT, increase the risk
of asthma-related death. A placebo controlled study with another LABA
(salmeterol) showed an increase in asthma-related deaths in patients
receiving salmeterol. This finding with salmeterol is considered a class
effect of LABA, including formoterol. Currently available data are
inadequate to determine whether concurrent use of inhaled corticosteroids
or other long-term asthma control drugs mitigates the increased risk of
asthma-related death from LABA. Available data from controlled clinical
trials suggest that LABA increase the risk of asthma-related
hospitalization in pediatric and adolescent patients
oWhen treating patients with asthma, prescribe SYMBICORT only for patients
not adequately controlled on a long-term asthma control medication, such
as an inhaled corticosteroid or whose disease severity clearly warrants
initiation of treatment with both an inhaled corticosteroid and LABA. Once
asthma control is achieved and maintained, assess the patient at regular
intervals and step down therapy (eg, discontinue SYMBICORT) if possible
without loss of asthma control, and maintain the patient on a long-term
asthma control medication, such as an inhaled corticosteroid. Do not use
SYMBICORT for patients whose asthma is adequately controlled on low or
medium dose inhaled corticosteroids
SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers
to treat acute symptoms.
It is possible that systemic corticosteroid effects such as hypercorticism and
adrenal suppression may occur, particularly at higher doses. Particular care
is needed for patients who are transferred from systemically active
corticosteroids to inhaled corticosteroids. Deaths due to adrenal
insufficiency have occurred in asthmatic patients during and after transfer
from systemic corticosteroids to less systemically available inhaled
Patients who are receiving SYMBICORT should not use additional formoterol or
other LABA for any reason.
Due to possible immunosuppression, potential worsening of infections could
occur. A more serious or even fatal course of chickenpox or measles can occur
in susceptible patients.
Excessive beta-adrenergic stimulation has been associated with central nervous
system and cardiovascular effects. SYMBICORT, like all products containing
sympathomimetic amines, should be used with caution in patients with
convulsive disorders, thyrotoxicosis, and cardiovascular disorders, especially
coronary insufficiency, cardiac arrhythmias, and hypertension. Beta-adrenergic
agonist medications may produce hypokalemia and hyperglycemia in some
patients. As with other inhaled medications, paradoxical bronchospasm may
occur with SYMBICORT. Use with caution in patients with diabetes mellitus.
Long-term use of orally inhaled corticosteroids, such as budesonide, a
component of SYMBICORT, may result in a reduction in growth velocity and/or a
loss of bone mineral density.
Glaucoma, increased intraocular pressure, and cataracts have been reported
following the inhaled administration of corticosteroids, including budesonide,
a component of SYMBICORT.
In rare cases, patients on inhaled corticosteroids may present with systemic
SYMBICORT should be administered with caution to patients being treated with
MAO inhibitors or tricyclic antidepressants, or within 2 weeks of
discontinuation of such agents. Caution should also be exercised in patients
on long-term ketoconazole and other known potent CYP3A4 inhibitors.
The most common adverse reactions ≥3% reported in clinical trials included
nasopharyngitis, headache, upper respiratory tract infection,
pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion,
stomach discomfort, vomiting, and oral candidiasis.
SYMBICORT is indicated for the treatment of asthma in patients 12 years and
older (also see Boxed WARNING).
SYMBICORT is NOT indicated for the relief of acute bronchospasm and should not
be initiated in patients during rapidly deteriorating or potentially
life-threatening episodes of asthma.
Please see full Prescribing Information, including Boxed WARNING.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.
For more information about AstraZeneca in the US or our AZ&Me™ Prescription
Savings programs, please visit:www.astrazeneca-us.comor call 1-800-AZandMe
SYMBICORT is a registered trademark, and AZ&Me is a trademark, of the
AstraZeneca group of companies.
©2013 AstraZeneca. All rights reserved.
Media Inquiries US:
Elizabeth Renz 302-885-1936 Elizabeth.Renz@astrazeneca.com
Press spacebar to pause and continue. Press esc to stop.